A molecular analysis of human oesophageal cancers reveals abnormalities that might be targetable by existing drugs, and indicates that the current stratification of these tumours into subtypes is incomplete. See Article p.169
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
The Cancer Genome Atlas Research Network. Nature 541, 169–175 (2017).
Torre, L. A. et al. CA Cancer J. Clin. 65, 87–108 (2015).
Weinstein, J. N. et al. Nature Genet. 45, 1113–1120 (2013).
Shibata, T. et al. Neoplasia 13, 864–873 (2011).
Mukai, S. et al. Ann. Surg. Oncol. http://dx.doi.org/10.1245/s10434-016-5100-z (2016).
Wang, W. et al. Lung Cancer 63, 23–31 (2009).
Staudinger, M. et al. Blood Cancer J. 4, e219 (2014).
Hiramatsu, K. et al. Cancer Sci. 106, 1474–1478 (2015).
The Cancer Genome Atlas Network. 517, 576–582 (2015).
The Cancer Genome Atlas Research Network. Nature 513, 202–209 (2014).
Author information
Authors and Affiliations
Corresponding authors
Related links
Rights and permissions
About this article
Cite this article
Peyser, N., Grandis, J. Spot the difference. Nature 541, 162–163 (2017). https://doi.org/10.1038/nature21112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature21112
This article is cited by
-
Minimalist approaches to cancer tissue-of-origin classification by DNA methylation
Modern Pathology (2020)
-
Metabolic reprogramming in clear cell renal cell carcinoma
Nature Reviews Nephrology (2017)
-
Correction
Nature (2017)
